Ritlecitinib
CAS 1792180-81-4Small Molecule
Overview
Ritlecitinib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4085457).
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Ritlecitinib expires 17 Oct 2041 and exclusivity 23 Jun 2028. Generic API sourcing typically opens up once these lapse.
Chemical identity
- IUPAC name
- 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidin-1-yl]prop-2-en-1-one
- Canonical SMILES
- C[C@H]1CC[C@H](CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3
- InChIKey
- CBRJPFGIXUFMTM-WDEREUQCSA-N
Verified Supplier Partner
Do you supply Ritlecitinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.